Actively Recruiting

Phase Not Applicable
Age: 18Years - 50Years
FEMALE
NCT07229261

MitoQ to Improve Vascular Funciton in Preeclampsia

Led by Medical College of Wisconsin · Updated on 2026-05-01

80

Participants Needed

1

Research Sites

80 weeks

Total Duration

On this page

Sponsors

M

Medical College of Wisconsin

Lead Sponsor

B

Bill and Melinda Gates Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.

CONDITIONS

Official Title

MitoQ to Improve Vascular Funciton in Preeclampsia

Who Can Participate

Age: 18Years - 50Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Pregnant patients with a clinical diagnosis of preeclampsia with severe features (inpatient cohort)
  • Pregnant patients with a clinical diagnosis of preeclampsia without severe features (outpatient cohort)
  • Gestational age between 23+0 and 32+0 weeks for inpatient cohort
  • Gestational age between 23+0 and 34+0 weeks for outpatient cohort
  • Singleton pregnancy
  • Age between 18 and 50 years old
  • No indication for immediate delivery
  • Planned expectant management for inpatient cohort
  • Planned outpatient management for outpatient cohort
  • Able to consent and follow a 2-step command
  • English speaking
Not Eligible

You will not qualify if you...

  • Unable to stand from a chair without physical assistance (assistive device allowed)
  • History of blood clots in the extremities or conditions contraindicating thigh compression or transient ischemia
  • Chronic severe COVID-19 symptoms lasting more than 6 months
  • History of head trauma or concussion within the past 6 months
  • Comorbid neurological disorders
  • Peripheral vascular disease
  • Diagnosed myocardial infarction or arrhythmia in the previous year
  • Resting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg
  • Other significant medical conditions affecting study participation or safety as determined by the Primary Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

Loading map...

Research Team

J

Jennifer McIntosh, D.O., M.S.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here